Weight loss
A once-daily GLP-1 injection — FDA-approved as Victoza for diabetes and Saxenda for weight loss, with heart protection proven in a 9,000-patient trial.
Start here
Liraglutide is an FDA-approved, once-daily injection sold as Victoza for type 2 diabetes and Saxenda for weight management. It is a longer-lasting version of GLP-1, a natural gut hormone, and it lowers blood sugar, reduces appetite, and produced 5-10% body weight loss in trials. In the 9,340-patient LEADER trial it also cut major heart complications by 13% 7.
Liraglutide (Victoza/Saxenda) is a once-daily GLP-1 (a gut hormone that tells your brain you're full) hormone that your pancreas naturally makes—the synthetic version helps your body release insulin when blood sugar is high, makes you feel fuller on less food, and protects your heart.
Liraglutide is a 31-amino-acid copy of human GLP-1(7-37) (a natural gut hormone), 97% matching the native hormone. It has an Arg34 substitution (one amino acid swapped) and a C16 palmitic acid side chain (a fatty tail) attached at Lys26 through a γ-glutamic acid linker. The fatty tail makes it stick to albumin (a blood protein) (>98% plasma protein binding), which gives it a longer half-life (~13 hours; the time for half the drug to leave the body) and allows once-daily dosing. Liraglutide activates GLP-1 receptors on pancreatic beta cells (insulin-making cells) to release insulin only when blood sugar is high. It suppresses glucagon (a hormone that raises blood sugar) when blood sugar is high, slows gastric emptying (stomach emptying) to reduce blood sugar spikes after meals, and activates GLP-1 receptors in the brain to increase fullness and reduce appetite. Meta-analyses (studies that pool many trials) suggest liraglutide cuts cardiovascular events by 10–13% through several mechanisms.
Evidence check
Well studied in people
This has been through large human trials — the strongest kind of evidence. Scientists have tested it on many people and measured what actually happened.
Every numbered marker on this page links to one of the 7 sources at the bottom.
Weight Management
Liraglutide is one of the first FDA-approved anti-obesity medications, promoting 5–10% body weight loss at the 3.0 mg dose through central appetite suppression and delayed gastric emptying — with 61.5% of patients achieving clinically meaningful ≥5% weight loss in the SCALE program
Metabolic
Broad metabolic improvement, including a 0.9–1.6% drop in HbA1c (average blood sugar over about 3 months), glucose-dependent insulin release, lower glucagon (a hormone that raises blood sugar), better blood fat levels, and a modest blood pressure drop. Together these address several heart-disease risk factors at once
Healing & Recovery
Demonstrated landmark cardiovascular protection in the LEADER trial — a 13% reduction in major adverse cardiovascular events and a 22% reduction in cardiovascular death over a median 3.8 years of follow-up in 9,340 high-risk type 2 diabetes patients; nonfatal heart attack and stroke rates were also lower but not statistically significant
The most-asked question
Liraglutide is dose-escalated: the studies start everyone low and step the dose up on a schedule, so the right amount depends on the week you're on. The research-reported maintenance range is 1.2–1.8 mg, once daily.
Week 1
0.6 mg
FDA-label starting dose for both Victoza (type 2 diabetes) and Saxenda (weight management); used for the first week to improve GI tolerability before escalation 6.
Ongoing
1.2-1.8 mg
Victoza maintenance range for type 2 diabetes; dose increased to 1.2 mg after week 1 and to 1.8 mg if further glycemic control (keeping blood sugar steady) is needed 6.
Ongoing
3.0 mg
Saxenda maintenance dose for chronic weight management, reached by escalating 0.6 mg weekly (0.6 to 1.2 to 1.8 to 2.4 to 3.0 mg over 5 weeks) 6.
The ceiling: 3.0 (as determined by your healthcare provider based on individual response and tolerance) 6
Reconstitution, in plain words
Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for Liraglutide:
Add the recommended volume of bacteriostatic water to the Liraglutide vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.
Your dose of Liraglutide is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.
Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with Liraglutide's recorded schedule.
Injection sites & technique
Subcutaneous (under the skin) injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Timing
Administer Liraglutide at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
Liraglutide injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
Liraglutide should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
The honest list
These show up most often. They usually fade as your body adjusts.
Most frequent adverse effect (20–40% incidence), typically dose-dependent and most pronounced during the first weeks of therapy and dose escalation. Generally mild to moderate and transient 65.
What to do Gradual dose titration (stepping the dose up gradually) per prescribing schedule. Eat smaller, more frequent meals. Avoid high-fat or very large meals. Most patients develop tolerance within 4–8 weeks.
Occurs in 15–20% of patients, usually mild to moderate in severity. Linked to the drug's GLP-1 (a gut hormone that tells your brain you're full) effects on gut movement 6.
What to do Stay well hydrated. Dietary adjustments (BRAT diet if needed). Usually self-limiting within the first few weeks of therapy.
Reported in 9–15% of patients, typically during dose escalation. Dose-dependent and generally decreases with continued therapy 6.
What to do Slow dose titration (stepping the dose up gradually). Temporarily hold at current dose if vomiting is persistent. Anti-emetics may be used short-term if needed.
Reduced appetite (therapeutic effect for weight management) and headache (5–10%) are common during initiation. Constipation (10–15%) may also occur.
What to do Appetite reduction is expected and therapeutic. Headache typically resolves with hydration and time. Constipation managed with adequate fiber and fluid intake.
Worth knowing about, but most people never see these.
Localized redness, swelling, or irritation at the subcutaneous (under the skin) injection site. Reported in 2–5% of patients.
What to do Rotate injection sites between abdomen, thigh, and upper arm. Ensure proper injection technique. Usually mild and self-resolving.
Rare, but if any of these happen, stop and contact a medical professional.
Acute pancreatitis (sudden inflammation of the pancreas) reported in 0.1–0.2% of patients. Risk factors include gallstones, very high blood triglycerides (blood fats) (>300 mg/dL), and a history of pancreatitis. 6 It shows up as severe, persistent belly pain, sometimes spreading to the back.
What to do Discontinue liraglutide immediately if pancreatitis is suspected. Do not restart after confirmed pancreatitis. Educate patients on warning signs: severe persistent abdominal pain with/without vomiting.
Cholelithiasis and cholecystitis occur at higher rates (3.1% vs 1.9% placebo in LEADER 7). Mechanism likely related to rapid weight loss altering bile composition and gallbladder motility.
What to do Monitor for symptoms of gallbladder disease (right upper quadrant pain, jaundice, fever). Imaging evaluation if suspected. May require cholecystectomy in severe cases.
Week by week
Is it right for you?
Liraglutide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Use with caution—discuss with your healthcare provider.
Use with caution—discuss with your healthcare provider.
Use with caution—discuss with your healthcare provider.
May be used together under medical guidance.
May be used together under medical guidance.
May be used together under medical guidance.
Generally safe to take alongside Liraglutide. Space doses apart if taking oral formulations to ensure optimal absorption.
Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Liraglutide is particularly well-suited for people with type 2 diabetes and an HbA1c (average blood sugar over about 3 months) above 7% who need both blood sugar control and weight management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach 3.
Liraglutide is particularly well-suited for individuals focused on obese individuals (bmi ≥30) or overweight (bmi ≥27) with weight-related comorbidities seeking fda-approved pharmacotherapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach 6.
Liraglutide is particularly well-suited for individuals focused on patients with established cardiovascular disease or high cardiovascular risk seeking cardioprotective diabetes therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach 7.
Liraglutide is particularly well-suited for individuals focused on patients on metformin requiring add-on therapy with favorable weight and cardiovascular profile. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach 3.
Liraglutide (Victoza, Saxenda) is FDA-approved, with extensive safety data from 15+ years of clinical use in diabetes (as a GLP-1 (a gut hormone that tells your brain you're full) agonist (a compound that switches a receptor on)) and obesity. Stomach and gut side effects (nausea, vomiting, diarrhea) occur in 30-40% of patients during dose increases 6 but ease significantly after 2-3 weeks of stable dosing. Black box warnings include risk of medullary thyroid carcinoma (a rare thyroid cancer) and pancreatitis, though the absolute incidence remains rare. Injection site reactions are minimal. It shows no liver or kidney toxicity or major drug interactions at approved doses.
Liraglutide safety derives from LEAD Phase 3 diabetes trials (2008-2009) enrolling thousands of patients, SCALE obesity trials (2013-2014), and decades of post-marketing surveillance. Published in New England Journal of Medicine and Diabetes Care, these studies establish favorable cardiovascular 7 outcomes and weight reduction with well-characterized adverse event profiles. Regulatory oversight by FDA and EMA continues monitoring thyroid-related safety signals.
Keeping it good
Store Liraglutide in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Once reconstituted, Liraglutide should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Not our opinion — the published record
2025
Liraglutide's heart benefits work through several pathways: HbA1c reduction (38%), better kidney function (18%), and lower blood pressure (7%) in varied patient groups. (HbA1c is a blood test of average blood sugar over about 3 months.)
Peng ZY, Lee YH, Ou HT
2024
Research (2024) on liraglutide adds important scientific knowledge about how it works in the body and acts as a drug.
Hamed K, Alosaimi MN, Ali BA
2023
Research (2023) shows liraglutide works as a treatment in clinical use.
Xie Z, Hu J, Gu H
2020
Clinical evidence (2020) supports using liraglutide as a medical treatment.
Ali AM, Martinez R, Al-Jobori H
2011
Clinical evidence (2011) supports using liraglutide as a medical treatment.
Ryan GJ, Hardy Y
2023
Current SAXENDA label (DailyMed, Novo Nordisk): boxed warning (the strongest FDA warning) for thyroid C-cell tumors; contraindicated (must not be used) with a personal or family history of MTC (medullary thyroid cancer) or MEN 2 (a genetic condition that causes tumors in hormone glands) and with hypersensitivity (allergy) to liraglutide. The recommended dose is 3 mg daily, reached by raising the dose by 0.6 mg each week. Nausea is the most frequent stomach and gut reaction (39% vs 14% with placebo). NOTE: the pregnancy contraindication was REMOVED from the label in 05/2025. The earlier accessdata.fda.gov link (2023 revision) now returns a 404 error (page not found).
Novo Nordisk
2016
LEADER randomly assigned 9,340 patients with type 2 diabetes at high cardiovascular risk. Over a median of 3.8 years, liraglutide lowered the primary MACE composite (a combined count of cardiovascular death, nonfatal heart attack and nonfatal stroke) (HR 0.87, P=0.01 for superiority) and cardiovascular death (HR 0.78). (HR, hazard ratio, compares risk against placebo; below 1 means lower risk.) Nonfatal heart attack, nonfatal stroke and hospitalization for heart failure were lower, but not by a statistically significant amount.
Marso SP, Daniels GH, Brown-Frandsen K, et al.
If this isn't the right fit
Your questions
Victoza and Saxenda both contain liraglutide but are prescribed for different conditions. Victoza (1.2–1.8 mg daily) is FDA-approved for type 2 diabetes to improve blood sugar control, while Saxenda (3.0 mg daily) is approved for chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities. They should not be used together or with any other GLP-1 receptor agonist (a drug that mimics the gut's fullness hormone).
Liraglutide promotes weight loss through two main mechanisms: it activates GLP-1 (a gut hormone that tells your brain you're full) receptors in the hypothalamus (the brain region that runs your hormone system) and brainstem to reduce appetite and increase feelings of fullness (satiety), and it delays gastric emptying so food stays in the stomach longer, further promoting satiety. Unlike stimulant-based weight loss drugs, liraglutide works through natural hormonal pathways that regulate hunger.
The LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) was a landmark randomized controlled trial of 9,340 patients with type 2 diabetes and high cardiovascular risk, followed for 3.5–5 years. It demonstrated that liraglutide reduced major adverse cardiovascular events by 13%, cardiovascular death by 22%, and was the first GLP-1 receptor agonist (a drug that mimics the gut's fullness hormone) to prove cardiovascular superiority in a large outcomes trial.
In rodent studies, liraglutide caused thyroid C-cell tumors (including medullary thyroid carcinoma, a rare type of thyroid cancer) at doses above those used in people. However, rodents have far more GLP-1 (a gut hormone that tells your brain you're full) receptors on thyroid C-cells than humans, and no cases of medullary thyroid carcinoma attributable to liraglutide have been confirmed in human clinical trials. The black box warning (the FDA's strongest warning) is precautionary, and liraglutide is contraindicated (must not be used) in patients with a personal or family history of MTC or MEN2 syndrome (an inherited condition that raises the risk of certain endocrine tumors).
Yes, liraglutide can be combined with basal insulin (such as insulin glargine or degludec). However, the insulin dose should be reduced when starting liraglutide to lower the risk of low blood sugar. The fixed-ratio combination Xultophy (insulin degludec + liraglutide) is designed for this purpose. Liraglutide should not be combined with prandial (mealtime) insulin without careful medical supervision.
Both are GLP-1 receptor agonists (drugs that mimic the gut's fullness hormone) from Novo Nordisk, but semaglutide (Ozempic/Wegovy) offers once-weekly dosing and generally greater weight loss (up to 15% body weight at higher doses) compared to liraglutide's daily dosing and 5–10% weight loss. Liraglutide has a longer safety track record (approved since 2010) and more extensive cardiovascular outcomes data. The choice depends on individual patient factors including dosing preference, weight loss goals, and insurance coverage.
7 sources
Every numbered marker on this page points to one of these. Same sources, same numbering as the Liraglutide research profile on Peptide Initiative.
Want the deep science?
Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.
Open the research profileThis guide is education, not medical advice. Talk to a clinician before taking anything.
PeptideGeek